Researchers looked at the results for patients with early-stage or locally advanced breast cancer. These patients received neoadjuvant chemotherapy before undergoing breast-conserving surgery. The study analyzed data from nearly 4,000 patients across several different studies to see how the treatment affected surgical margins.
The findings showed that the rate of tumor-on-ink margin positivity was 9.7 percent. This rate is comparable to what is typically seen in primary surgery without prior chemotherapy. However, the rate of re-excision was found to be 14.0 percent. This specific rate was noted to be more variable across different studies.
Patients with certain types of cancer, such as invasive lobular carcinoma or residual DCIS, were more likely to have positive margins or require re-excision. Because of the differences between studies, these results should be viewed as a general overview. Patients should talk to their doctors about how these specific findings apply to their personal treatment plan.
Common questions
What is the risk of needing a second surgery after chemotherapy?
The study found a re-excision rate of 14.0 percent for patients who received neoadjuvant chemotherapy followed by breast-conserving surgery. However, this rate showed significant variation between different studies. Patients with invasive lobular carcinoma or residual DCIS were more likely to experience these higher rates of re-excision.
Does chemotherapy before surgery affect the surgical margins?
The study found that the rate of tumor-on-ink margin positivity was 9.7 percent. This result is comparable to the rates typically seen in primary surgery without prior chemotherapy. This suggests that the chemotherapy did not significantly change the likelihood of a positive margin compared to standard surgery.
Who is most at risk for positive margins after chemotherapy?
The data indicates that patients with residual DCIS and invasive lobular carcinoma are associated with higher rates of margin positivity and re-excision. You should discuss your specific diagnosis with your oncology team to understand how these risks apply to your case.
